TRIAMCINOLONE ACETONIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (1960)
Entry Type: Small molecule
Molecule Category: Parent
UNII: F446C597KA

Structure
InChI Key YNDXUCZADRHECN-JNQJZLCISA-N
Smile CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
InChI
InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H31FO6
Molecular Weight 434.5
AlogP 2.42
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 93.06
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 31.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- - - - 32
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -10.99--3.3
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
- 4.414 - 2.006 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
- 179 - 23 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 115.53

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Bursitis 4 D002062 ClinicalTrials
Choroidal Neovascularization 3 D020256 ClinicalTrials
Osteoarthritis, Knee 3 D020370 ClinicalTrials
Dupuytren Contracture 3 D004387 ClinicalTrials
Retinal Vein Occlusion 3 D012170 ClinicalTrials
Uveitis 3 D014605 ClinicalTrials
Optic Neuropathy, Ischemic 3 D018917 ClinicalTrials
Macular Degeneration 3 D008268 ClinicalTrials
Pemphigus 3 D010392 ClinicalTrials
Chalazion 3 D017043 ClinicalTrials
Vitreoretinopathy, Proliferative 3 D018630 ClinicalTrials
Cystitis, Interstitial 3 D018856 ClinicalTrials
Lichen Planus, Oral 3 D017676 ClinicalTrials
Rhinitis 3 D012220 ClinicalTrials
Eye Injuries 3 D005131 ClinicalTrials
Macular Degeneration 3 D008268 ClinicalTrials
Osteoarthritis, Hip 3 D015207 ClinicalTrials
Radiculopathy 3 D011843 ClinicalTrials
Macular Edema 3 D008269 ClinicalTrials
Tendinopathy 3 D052256 ClinicalTrials
Otitis Media with Effusion 3 D010034 ClinicalTrials
Cough 3 D003371 ClinicalTrials
Macular Edema 3 D008269 ClinicalTrials
Diabetic Retinopathy 3 D003930 ClinicalTrials
Uveomeningoencephalitic Syndrome 2 D014607 ClinicalTrials
Ulnar Neuropathies 2 D020424 ClinicalTrials
Humeral Fractures 2 D006810 ClinicalTrials
Glaucoma 2 D005901 ClinicalTrials
Lichen Planus 2 D008010 ClinicalTrials
Pemphigoid, Benign Mucous Membrane 2 D010390 ClinicalTrials
Keloid 2 D007627 ClinicalTrials
Uveal Melanoma 2 D000098943 ClinicalTrials
Dermatitis, Atopic 2 D003876 ClinicalTrials
Hand Dermatoses 2 D006229 ClinicalTrials
Wet Macular Degeneration 2 D057135 ClinicalTrials
Psoriasis 2 D011565 ClinicalTrials
Shoulder Pain 2 D020069 ClinicalTrials
Cataract 2 D002386 ClinicalTrials
Vitiligo 2 D014820 ClinicalTrials
Alopecia Areata 2 D000506 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Complex Regional Pain Syndromes 2 D020918 ClinicalTrials
Tendon Entrapment 1 D053682 ClinicalTrials
Fibroma 1 D005350 ClinicalTrials
Mucositis 1 D052016 ClinicalTrials
Rotator Cuff Injuries 1 D000070636 ClinicalTrials
Hearing Loss 1 D034381 ClinicalTrials
Neuroma, Acoustic 1 D009464 ClinicalTrials
Papilledema 1 D010211 ClinicalTrials

Related Entries

MCS

Scaffolds

Mixture
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
18.65
Injury, poisoning and procedural complications
9.59
Nervous system disorders
8.46
Skin and subcutaneous tissue disorders
7.85
Respiratory, thoracic and mediastinal disorders
7.08
Eye disorders
6.86
Vascular disorders
6.21
Psychiatric disorders
4.76
Gastrointestinal disorders
4.3
Infections and infestations
3.93
Musculoskeletal and connective tissue disorders
3.74
Metabolism and nutrition disorders
2.97
Cardiac disorders
2.73
Endocrine disorders
2.61
Immune system disorders
2.55
Investigations
2.45

Cross References

Resources Reference
ChEBI 71418
ChEMBL CHEMBL1504
DrugCentral 2726
EPA CompTox DTXSID6021371
FDA SRS F446C597KA
Guide to Pharmacology 2867
KEGG C08183
PDB 1TA
PubChem 6436
SureChEMBL SCHEMBL4689
ZINC ZINC000003875481
CONTENTS